slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 228,361-228,390
Pages 10,126
Rows per page 30
Component
228,361-228,390 of 303,780
16
The slide outlines a clinical trial protocol for Olvi-Vec in ovarian cancer.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
17
Includes Kaplan-Meier survival curves and dose escalation scatter plots for two distinct patient groups.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
18
Includes specific patient case reports (Pt #21A-06 and Pt #21A-04) showing tumor response metrics.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
19
Includes a bio for Benny Li, PhD, CEO of Newsoara.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
20
The slide highlights the strategic partnership and the division of commercial rights between Genelux and Newsoara.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
21
The slide highlights the synergy between two distinct therapeutic approaches (oncolytic immunotherapy and adoptive cell therapy).Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
22
The slide uses a hub-and-spoke style layout to categorize strategic pillars.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
23
The slide uses a document-style callout for key takeaways and circular image containers for facility locations.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
24
The slide categorizes the library into therapeutic genes, immune modularity, and therapeutic antibodies.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
25
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
27
Includes specific financial metrics and analyst names.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
28
The slide uses a dual-track timeline approach: one for executed milestones (left) and one for future goals (right).Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
29
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
30
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
31
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
34
Includes histological images of patient samples (Pt.#15A-01 and Pt.#15A-11) showing tumor cell elimination and lymphocyte infiltration.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
35
The slide uses histology images and HALO infiltration histograms to demonstrate the mechanism of action and clinical efficacy.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
36
The slide uses a combination of immunological data (ELISPOT) and clinical imaging data (SLD) to show causality between immune response and tumor shrinkage.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
37
The slide uses clinical data (cytokine levels and PD-L1 staining) to support the mechanism of action.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
02
GMS | Results Presentation Deck | 19 slidesGMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations Beat · Attention1 hit
03
Includes a disclaimer regarding non-GAAP metrics at the bottom.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations Beat · Attention1 hit
04
The slide uses a four-column layout to detail strategic initiatives and recent progress for each.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
05
The slide uses a combination of summary text, callouts for specific financial impacts, and detailed tables for per-day sales and organic growth metrics.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
07
Includes footnotes detailing reconciliation and definitions.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
08
The slide uses a table to compare performance metrics across different product lines.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
09
Includes footnotes regarding reconciliation and tax rate definitions.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
10
GMS | Results Presentation Deck | 19 slidesGMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
11
Includes operational metrics like branch count and net sales per business day.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
12
Includes supplemental cash flow disclosures and a non-GAAP reconciliation for free cash flow.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
13
The table includes a footnote explaining the organic net sales growth calculation.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit